{"prompt": "['PREDM', 'Page 37', '8.3 Subject Compliance Monitoring', 'Participant adherence to metformin will be monitored by virtual pill counts conducted', 'using a web-based meeting by the study team on week 2, 4, 8, 15 and 20, the protocol', 'will be adapted from Kalichman et al.39 In-person pill counts will be performed on', 'weeks 12 and 24 to assess adherence for the prior 4 weeks and confirm virtual pill', 'count assessments. Adherence to the lifestyle change program will primarily be', 'assessed by review of the log of lesson completion at the time of study completion.', 'We will also collect data on lesson completion, self-reported weight, food logging,', 'activity logging, participation with coach messages, participation with peer groups,', 'dates and frequency of app access, time spent in application.', '9.0 OFF STUDY AND OFF THERAPY CRITERIA', '9.1 Off study criteria', 'Death', 'Lost to follow-up', 'Request of the Participant', 'Discretion of the Study PI, such as the following:', 'The researcher decides that continuing in the study would be harmful', 'A treatment is needed that is not allowed on this study', 'The participant misses so many appointments that the data cannot be', 'used in the study. Specifically, a participants data will not be evaluable', 'for efficacy endpoints (secondary) if they are not assessed within 3', 'weeks of the end of therapy time point (24 week visit) and will not be', 'evaluable for interim efficacy if they are not assessed within 3 weeks of', 'the interim campus visit time point (12 week visit). However, because', 'the primary aim of the study is feasibility, participants will not be taken', 'off study for non-adherence or missed appointments, of course, drug', 'will not be dispensed (and therefore they will be non-adherent to the', 'metformin intervention) until contacted and adherence and adverse', 'events assessed by the study coordinator.', 'The participant develops diabetes requiring additional treatment (if', 'FPG > 126 mg/dl but < 140 mg/dL or HbA1c > 6.5% but <7.0% and', \"the patient's PCP does not feel alternate therapy would benefit the\", 'patient they may remain on study as metformin + lifestyle change are', 'typical first line diabetes management strategies)', 'New information is learned that a better treatment is available, or that', \"the study is not in the participant's best interest\", 'Completion of week 24 evaluations', \"St. Jude Children's Research Hospital\", 'Initial version, dated: 04-10-20', 'IRB approkB date 00-00-00', 'NUMBER: 20-0550', 'Protocol document date: 10-12-2020', 'IRB APPROVAL DATE: 11/10/2020']['PREDM', 'Page 38', '9.2 Off therapy criteria', 'Development of unacceptable toxicity during treatment', 'Refusal of therapy', 'Discretion of the Study PI, such as the following:', 'The researcher decides that continuing in the study would be harmful', 'A treatment is needed that is not allowed on this study', 'The participant misses so many appointments that the data cannot be', 'used in the study. Specifically, drug will not be dispensed unless the', 'participant is contacted and adherence assessed within the timepoints', 'detailed in the study schema; however, participants will remain enrolled', 'in the lifestyle change program throughout the duration of the study.', 'The participant develops diabetes requiring additional treatment (if', 'FPG 126 mg/dl but < 140 mg/dL or HbA1c > 6.5% but <7.0% and', \"the patient's PCP does not feel alternate therapy would benefit the\", 'patient they may remain on study as metformin + lifestyle change are', 'typical first line diabetes management strategies)', 'New information is learned that a better treatment is available, or that', \"the study is not in the participant's best interest\", 'Completion of week 24 evaluations', '10.0 SAFETY AND ADVERSE EVENT REPORTING REQUIREMENTS', '10.1 Adverse Events (AEs)', 'Adverse events will be monitored from the time of first study intervention or', 'treatment. Participants will be instructed to report all AEs during the study and', 'will be assessed for the occurrence of AEs throughout the study.', '10.2 Definitions', 'Adverse Event (AE): Any untoward medical occurrence associated in a study', 'participant after the first treatment or intervention on study. Adverse Events will be', 'graded by the NCI CTCAE version 5.0.', 'Serious Adverse Event (SAE): Any adverse event temporally associated with the', \"subject's participation in research that meets any of the following criteria:\", 'results in death;', 'is life-threatening (places the subject at immediate risk of death from the', 'event as it occurred);', 'requires inpatient hospitalization or prolongation of existing', 'hospitalization;', 'results in a persistent or significant disability/incapacity;', 'results in a congenital anomaly/birth defect; or', \"St. Jude Children's Research Hospital\", 'Initial version, dated: 04-10-20', 'IRB approkB date 00-00-00', 'NUMBER: 20-0550', 'Protocol document date: 10-12-2020', 'IRB APPROVAL DATE: 11/10/2020']\n\n###\n\n", "completion": "END"}